
    
      The primary purpose of Parts A and B of this study is to determine a recommended dose level
      of prexasertib (an inhibitor of checkpoint kinase 1[Chk-1]) in combination with cisplatin and
      radiation therapy (Part A) or cetuximab and radiation therapy (Part B) in participants with
      locally advanced head and neck cancer.
    
  